Publicaciones en colaboración con investigadores/as de Universidad de la República (41)

2024

  1. Flavonoid-Quinoxaline Hybrid Compounds as Cathepsin Inhibitors Against Fascioliasis

    ChemMedChem, Vol. 19, Núm. 18

  2. Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 49, Núm. 4, pp. 507-516

2023

  1. Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1115-1126

  2. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation

    European Journal of Pharmaceutical Sciences, Vol. 183

2021

  1. Enteric reabsorption processes and their impact on drug pharmacokinetics

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Clinical pharmacology of cannabidiol in refractory epilepsy

    Farmacia Hospitalaria, Vol. 44, Núm. 5, pp. 222-229

2019

  1. Iberoamerican Pharmacometrics Network Congress 2018 Report: Fostering Modeling and Simulation Approaches for Drug Development and Regulatory and Clinical Applications in Latin America

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 8, Núm. 4, pp. 197-200

2018

  1. Changes in plasma fatty acid composition are associated with improvements in obesity and related metabolic disorders: A therapeutic approach to overweight adolescents

    Clinical Nutrition, Vol. 37, Núm. 1, pp. 149-156

2017

  1. Development, validation and application of a GC–MS method for the simultaneous detection and quantification of neutral lipid species in Trypanosoma cruzi

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 1061-1062, pp. 225-232

  2. Relation between plasma antioxidant vitamin levels, adiposity and cardio-metabolic profile in adolescents: Effects of a multidisciplinary obesity programme

    Clinical Nutrition, Vol. 36, Núm. 1, pp. 209-217

2016

  1. Synthesis and biological evaluation of quinoxaline di-N-oxide derivatives with in vitro trypanocidal activity

    Bioorganic and Medicinal Chemistry Letters, Vol. 26, Núm. 3, pp. 903-906

2013

  1. Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents

    European Journal of Medicinal Chemistry, Vol. 66, pp. 324-334

  2. Phenazine N,N′-dioxide scaffold as selective hypoxic cytotoxin pharmacophore. Structural modifications looking for further DNA topoisomerase II-inhibition activity

    MedChemComm, Vol. 4, Núm. 3, pp. 595-607

2011

  1. 3-trifluoromethylquinoxaline N, N′-dioxides as anti-Trypanosomatid agents. Identification of optimal anti- T. cruzi agents and mechanism of action studies

    Journal of Medicinal Chemistry, Vol. 54, Núm. 10, pp. 3624-3636

  2. Genetic toxicology and preliminary in vivo studies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents

    Drug and Chemical Toxicology, Vol. 34, Núm. 3, pp. 285-293

2010

  1. Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers

    Bioorganic and Medicinal Chemistry, Vol. 18, Núm. 14, pp. 5391-5399

  2. Structural modifications on the phenazine N,N′-dioxide-scaffold looking for new selective hypoxic cytotoxins

    European Journal of Medicinal Chemistry, Vol. 45, Núm. 11, pp. 5362-5369

  3. Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation

    Bioorganic and Medicinal Chemistry, Vol. 18, Núm. 12, pp. 4433-4440

2009

  1. Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction

    Toxicology Letters, Vol. 190, Núm. 2, pp. 140-149

  2. Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs

    Molecules, Vol. 14, Núm. 6, pp. 2256-2272